# Phenylbutyrate/Genistein Duotherapy in Delta F508-Heterozygotes (for Cystic Fibrosis)

> **NCT00590538** · PHASE1,PHASE2 · TERMINATED · sponsor: **Children's Hospital of Philadelphia** · enrollment: 9 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Sodium 4-Phenylbutyrate
- **DRUG:** Genistein (Unconjugated Isoflavones 100)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00590538
- **Lead sponsor:** Children's Hospital of Philadelphia
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-02
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** 12/15/2008 Voluntarily placed on inactive status-requested by the PI
- **Last updated:** 2011-06-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00590538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00590538, "Phenylbutyrate/Genistein Duotherapy in Delta F508-Heterozygotes (for Cystic Fibrosis)". Retrieved via AI Analytics 2026-09-22 from https://api.ai-analytics.org/clinical/NCT00590538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*